News
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Nov 5, 12:15 PM·
Medium Optimistic

Sources

Summarized by i88

Tickers

Summary

Amylyx Pharmaceuticals (NASDAQ: AMLX) discussed on its Q3 2026 earnings call, held November 5, 2026, its plans to file for U.S. approval of its experimental post-bariatric hypoglycemia treatment by the end of 2026, following positive late-stage trial results. The company is preparing for a potential launch in 2027.

Amylyx Pharmaceuticals (NASDAQ: AMLX) discussed plans to file for U.S. approval of its experimental post-bariatric hypoglycemia treatment by the end of 2026, following positive late-stage trial results, on its third-quarter 2026 earnings call held November 5, 2026.

The company is preparing for a potential launch in 2027, according to the call.

Call details

  • Event: Amylyx Pharmaceuticals Q3 2026 Earnings Call
  • Date and time: November 5, 2026, 8:00 AM EST
  • Ticker: AMLX

Company participants

  • Justin Klee — Co-CEO & Director
  • Camille Bedrosian — Chief Medical Officer
  • Dan Monahan — Chief Commercial Officer
  • James Frates — Chief Financial Officer
  • Joshua Cohen — Co-Founder, Co-CEO & Director
  • Courtney O’Leary

Conference call participants

  • Jacob Ormes — TD Securities Equity Research
  • Seamus Fernandez — Guggenheim Securities, LLC, Research Division
  • Geoffrey Meacham — Citigroup Inc. Exchange Research
  • Marc Goodman — Leerink Partners LLC, Research Division
  • Michael DiFiore — Evercore ISI Institutional Equities, Research Division
  • Rami Katkhuda — LifeSci Capital, LLC, Research Division
  • James Condulis — Stifel, Nicolaus & Company, Incorporated, Research Division
  • Samuel Lee — Mizuho Securities USA LLC, Research Division
  • Dina Ramadane — BofA Securities, Research Division
  • Ananda Ghosh — H.C. Wainwright & Co, LLC, Research Division
  • Christopher Chen — Robert W.

The transcript was published on November 6, 2026.